Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.

Rugo, HS; Roche, Hoffmann-La; Thomas, E; T. Blackwell, Kim; Chung, Heeyoung; Lerzo, Guillermo; Volles, LA; Poulart, Valerie; A. Perez, Edith

doi:10.1158/0008-5472.sabcs-3057

Public

Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.

Published in Cancer Research • Jan 1, 2009

Authors:

HS Rugo

Hoffmann-La Roche

E Thomas

Abstract

Abstract Abstract #3057 Introduction: Patients (pts) with ER/PR/HER2 negative advanced breast cancer (triple negative, TN, basal-like) have limited treatment options and a poor prognosis. Ixabepilone (ixa), the first in a new class of antineoplastic agents, showed clinical benefit in combination wit...

Subject

Capecitabine

Ixabepilone

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!